Monday, January 14, 2019 4:41:17 AM
Call for doctors to join in better approach for dementia care
14 January 2019
Leading Australian dementia care service providers have today highlighted concerns about the use of strong medications in dementia care – including the role of prescribing doctors – while also pointing to the benefits of relationship-based care.
Alzheimer’s Australia research has shown that up to 80 per cent of aged care residents with dementia have been prescribed psychotropic medications while the recent INSPIRED study shows that relational dementia care in home-style settings can reduce the use of inappropriate medication by 52 per cent.
HammondCare Chief Executive Dr Stephen Judd said today that any focus on this important issue was welcome and should include consideration of the role of doctors, rather than simply pointing the finger at aged care providers.
“Part of this conversation must include the medical profession being willing to be accountable for the prescribing practices of some of its members,” Dr Judd said.
“And that doesn't start on the day an older person moves into residential care. Our experience is that often individuals come in with their lists of medications which may be inappropriately prescribed.”
Meanwhile, Prof Stephen Macfarlane, Head of Clinical Services for Dementia Support Australia agreed that there was an over-reliance on psychotropic medication, particularly when the marginal benefit of drugs is “dwarfed by the positive outcomes from behavioural, psychological and environmental interventions that can be put in place instead.”
In regard to the role of doctors in prescribing, he agreed there needed to be a shared approach to improvements.
“Clearly, a doctor is responsible for writing a script. If they think a script is inappropriate in the circumstances, they simply shouldn’t write it. This is the essence of accountability.” Prof Macfarlane said.
“I think a factor that may contribute to inappropriate prescribing is the fear that, if the GP is new to the person and doesn’t know them well, changing medications in this circumstances will somehow destabilise the person.
“As well, I would question the adequacy of the training GP’s receive in treatment options for people with advanced dementia that might equip them to do other than prescribe.
“If a GP feels out of their depth in these circumstances, I suggest they refer to appropriate specialist services such as Dementia Support Australia.”
https://www.hammond.com.au/about/news/call-for-doctors-to-join-in-better-approach-for-dementia-care
14 January 2019
Leading Australian dementia care service providers have today highlighted concerns about the use of strong medications in dementia care – including the role of prescribing doctors – while also pointing to the benefits of relationship-based care.
Alzheimer’s Australia research has shown that up to 80 per cent of aged care residents with dementia have been prescribed psychotropic medications while the recent INSPIRED study shows that relational dementia care in home-style settings can reduce the use of inappropriate medication by 52 per cent.
HammondCare Chief Executive Dr Stephen Judd said today that any focus on this important issue was welcome and should include consideration of the role of doctors, rather than simply pointing the finger at aged care providers.
“Part of this conversation must include the medical profession being willing to be accountable for the prescribing practices of some of its members,” Dr Judd said.
“And that doesn't start on the day an older person moves into residential care. Our experience is that often individuals come in with their lists of medications which may be inappropriately prescribed.”
Meanwhile, Prof Stephen Macfarlane, Head of Clinical Services for Dementia Support Australia agreed that there was an over-reliance on psychotropic medication, particularly when the marginal benefit of drugs is “dwarfed by the positive outcomes from behavioural, psychological and environmental interventions that can be put in place instead.”
In regard to the role of doctors in prescribing, he agreed there needed to be a shared approach to improvements.
“Clearly, a doctor is responsible for writing a script. If they think a script is inappropriate in the circumstances, they simply shouldn’t write it. This is the essence of accountability.” Prof Macfarlane said.
“I think a factor that may contribute to inappropriate prescribing is the fear that, if the GP is new to the person and doesn’t know them well, changing medications in this circumstances will somehow destabilise the person.
“As well, I would question the adequacy of the training GP’s receive in treatment options for people with advanced dementia that might equip them to do other than prescribe.
“If a GP feels out of their depth in these circumstances, I suggest they refer to appropriate specialist services such as Dementia Support Australia.”
https://www.hammond.com.au/about/news/call-for-doctors-to-join-in-better-approach-for-dementia-care
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
